MYGN Earnings

MYGN reported its FY2025Q4 earnings on 2026-02-23, showcasing a revenue of 0.00 against an estimate of 208.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.1 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following MYGN's FY2025Q4 earnings announcement on 2026-02-23, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, MYGN's stock price tends to shift by an average of +0.87% in the 10 days leading up to earnings and -3.59% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate MYGN’s annual revenue to reach 207.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -0.01% and EPS estimates Revise Downward by -0.19% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between MYGN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -0.01%, while EPS estimates moved Revise Downward by -0.19% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MYGN's stock price typically moves by +0.87% in the 10 days before its earnings and -3.59% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 207.00M.

The earnings call reveals strong performance with raised revenue and EBITDA guidance, new product launches, and strategic partnerships. Despite some operational challenges, management's optimistic outlook, particularly in prenatal and cancer diagnostics, suggests potential growth. The Q&A highlights market expansion and improved customer workflows, reinforcing positive sentiment. However, unclear responses on ASP assumptions and reimbursement timelines introduce some uncertainty, slightly tempering the overall positive outlook.